Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system.
Ratings
0 / 5
0 ratings in the last 12 months
5
4
3
2
1
CEO
Mr. Adrian Gottschalk$221.8M
Market Cap • 24/04/20242015
(há 9 anos)
2020
(4 years ago)
NASDAQ
Listagem
Cambridge
Sede • Massachusetts161
N° de Empregados • 2022Valuation
Company FinancialsValuation Indicators
Valuation IndicatorsRetorno Histórico
FHTXSó no Premium...
Visualize o retorno de longo prazo das ações. Dividendos e outros eventos são considerados.